Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies.

Clinical chemistry·1995
Same author

Body composition and serum lipids in female runners: influence of exercise level and menstrual bleeding pattern.

European journal of clinical investigation·1995
Same author

Changes in the carboxyl-terminal propeptide of type I procollagen and other markers of bone formation upon five days of bed rest.

Bone·1995
Same author

Measurement of bone mineral density.

Calcified tissue international·1995
Same author

Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine, hip, and forearm: a human cadaver study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·1995
Same author

[The osteoporosis profile].

Ugeskrift for laeger·1995
Same journal

Correction to: Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Letter to the Editor: multiplicity, microbiome interventions, and measurement biases in bone health biomarkers.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Association between myosteatosis and bone mineral density in postmenopausal women.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Author response to the letter to the editor regarding "Hip Response to Romosozumab in Glucocorticoid Users: Beyond Systemic Bone Turnover Markers".

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Revisiting the Osteoporosis Self-Assessment Tool (OST): evidence from a multi-cohort study in Asia supporting age-dependent thresholds.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
See all related articles

Related Experiment Videos

Individualizing osteoporosis therapy.

S Silverman1, C Christiansen

  • 1Cedars-Sinai Medical Center and University of California, Los Angeles, CA, USA. stuarts@slsdss.net

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
|January 6, 2012
PubMed
Summary
This summary is machine-generated.

Individualized osteoporosis treatment selection balances efficacy, safety, and patient factors. First-line bisphosphonates are common, but newer agents offer tailored options for diverse patient needs.

Related Experiment Videos

Area of Science:

  • Endocrinology
  • Pharmacology
  • Geriatrics

Background:

  • Osteoporosis treatment guidelines exist but lack specific drug recommendations.
  • Therapy choice requires balancing efficacy, safety, cost, and convenience.

Purpose of the Study:

  • To outline an individualized approach to osteoporosis pharmacotherapy.
  • To review various osteoporosis drug classes and their specific indications.

Main Methods:

  • Review of current osteoporosis treatment guidelines and pharmacologic agents.
  • Discussion of drug characteristics including efficacy, safety, and administration.

Main Results:

  • Bisphosphonates are recommended as first-line therapy, especially for older adults.
  • Selective estrogen receptor modulators, hormone therapy, calcitonin, anabolic agents, strontium ranelate, and denosumab offer alternative or adjunctive options.
  • Individualized selection considers patient-specific factors and fracture risk.

Conclusions:

  • An individualized pharmacotherapy approach is crucial for optimizing osteoporosis treatment outcomes.
  • Incorporating newer agents into treatment paradigms will further enhance patient care.